Key result
Synergy everolimus-eluting stents (S-EES) demonstrated a significantly higher proportion of covered struts compared to Xience everolimus-eluting stents at 2 weeks (42.4% vs 26.3%, P<0.001) in patients with STEMI.
Why the study?
Does the bioabsorbable polymer-coated Synergy everolimus-eluting stent improve early neointimal strut coverage compared to the durable polymer-coated Xience everolimus-eluting stent in patients with STEMI?
Observational (n=47)
Single-blind
No
Does the bioabsorbable polymer-coated Synergy everolimus-eluting stent improve early neointimal strut coverage compared to the durable polymer-coated Xience everolimus-eluting stent in patients with STEMI?
Absolute Event Rate: 42.4% vs 26.3%
p-value: p=<0.001
Bioabsorbable polymer-coated Synergy everolimus-eluting stents demonstrated significantly faster early neointimal strut coverage compared to durable polymer-coated Xience stents in STEMI patients, suggesting a potential advantage in reducing early stent thrombosis risk.
S-EES showed better early strut coverage than X-EES in STEMI; leaves open impact on thrombosis risk.
BACKGROUND: Despite the revolution of coronary stents, there remain concerns about the risk of stent thrombosis, especially in patients with ST-elevation myocardial infarction (STEMI). The present study compared early vascular healing as a contributing factor to reducing stent thrombosis between Xience everolimus-eluting stents (X-EES) and Synergy everolimus-eluting stents (S-EES) in patients with STEMI. METHODS AND RESULTS: The present study included 47 patients with STEMI requiring primary percutaneous coronary intervention with X-EES (n=25) or S-EES (n=22). Optical coherence tomography (OCT) assessments of the stented lesions were performed 2 weeks and 4 months after stent implantation. Neointimal strut coverage, malapposition and the frequency of thrombus formation were evaluated. In the 2-week OCT analysis, the proportion of covered struts in S-EES (42.4±15.4%) was significantly higher than in X-EES (26.3±10.1%, P<0.001). In the 4-month OCT analysis, the proportion of covered struts in S-EES (72.2±17.9%) was still significantly higher than in X-EES (62.0±14.9%, P=0.04). CONCLUSIONS: Compared with X-EES, S-EES showed a higher proportion of covered struts in the early phase after stent implantation for STEMI patients.
No takes yet. Share an insight, caveat, or question.
Shimoda et al. (2018) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=47). Synergy everolimus-eluting stents (S-EES) vs. Xience everolimus-eluting stents (X-EES) was evaluated on Proportion of covered struts at 2 weeks (lesion-level analysis) (p=<0.001). Synergy everolimus-eluting stents (S-EES) demonstrated a significantly higher proportion of covered struts compared to Xience everolimus-eluting stents at 2 weeks (42.4% vs 26.3%, P<0.001) in patients with STEMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: